In scalp psoriasis, how does intralesional corticosteroid injection compare to topical corticosteroid therapy, and when is it appropriate?

Scalp Psoriasis: Topical vs Intralesional Corticosteroids

Topical corticosteroids (class 1-7) should be the first-line treatment for scalp psoriasis, with intralesional corticosteroids reserved specifically for localized, nonresponding, or very thick scalp lesions that have failed topical therapy. 1

Treatment Algorithm

First-Line: Topical Corticosteroids

The 2021 Joint AAD-NPF Guidelines provide a Level I evidence, Strength A recommendation for topical corticosteroids as initial and maintenance treatment of scalp psoriasis 1. This represents the highest quality evidence available and should guide your initial approach.

• Duration: Minimum of up to 4 weeks initially 1
• Potency selection: Any class (1-7) can be used for scalp, though higher potency (class 1-2) is often needed for thick plaques 1
• Efficacy: Ultrahigh-potency corticosteroids show 58-92% efficacy rates in clinical trials 1

Second-Line: Intralesional Corticosteroids

Reserve intralesional therapy for these specific scenarios:

1. Localized nonresponding lesions after adequate topical trial
2. Very thick plaques on the scalp that resist topical penetration
3. Residual plaques after systemic treatment requiring targeted control 1

Dosing protocol when indicated:

• Triamcinolone acetonide up to 20 mg/mL
• Frequency: Every 3-4 weeks
• Volume: Varies based on lesion size 1

Key Clinical Reasoning

The guideline explicitly positions intralesional therapy as an adjunctive approach, not a competing first-line option 1. This hierarchical structure exists for several important reasons:

Practical advantages of topical therapy:

• Non-invasive application
• Patient can self-administer at home
• Suitable for widespread scalp involvement
• Lower risk of localized adverse effects like atrophy

When intralesional becomes appropriate:

• Topical therapy fails to penetrate thick, hyperkeratotic plaques
• Patient has 1-3 isolated resistant plaques requiring targeted intervention
• Cosmetic or symptomatic control needed for specific visible areas 2

Critical Adverse Effect Considerations

Topical corticosteroid risks (generally mild for scalp):

• Skin atrophy (less common on scalp than face/intertriginous areas)
• Folliculitis
• Telangiectasia 1

Intralesional corticosteroid risks (more concerning):

• Localized atrophy (can be disfiguring but often reversible) 2
• Hypopigmentation at injection sites 2
• Pain during and after injection 2
• Potential for systemic absorption with large volumes

Common Pitfalls to Avoid

1. Don't jump to intralesional therapy prematurely: Ensure adequate topical trial (minimum 4 weeks with appropriate potency and patient adherence) before escalating 1

2. Don't use intralesional for widespread scalp disease: This approach is impractical and increases adverse effect risk. Consider systemic therapy instead 3, 4

3. Avoid systemic corticosteroids: While not directly asked, note that systemic corticosteroids can cause psoriasis flare-ups and morphology changes and should be avoided 5

4. Don't neglect vehicle selection for topicals: Solutions, foams, and gels are preferred for scalp application over ointments to improve compliance 4

Tapering Strategy

After clinical improvement with topical therapy, gradually reduce frequency rather than abrupt cessation to minimize rebound risk 1. The exact tapering protocol is not well-established, but this principle applies to both topical and intralesional approaches.